Ophthalmology

The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all tertiles.

Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.

The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.

The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.

Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.

Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.

13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).

Investigators advise an ophthalmologic evaluation at the time of tumor diagnosis to detect early vision loss.

In an attempt to halt the progression of dry AMD and geographic atrophy, the use of high-resolution optical coherence tomography becomes pivotal.

This research team conducted a cross-sectional multicenter study to report the ocular fundus manifestations in infants with congenital ZIKV exposure in French Guiana, Martinique, and Guadeloupe, French West Indies.

The investigators emphasized that hydroxychloroquine doses of 5 mg/kg/day or less, in accordance with current ophthalmology and rheumatology guidelines, was associated with a higher risk of lupus flares, and the threshold was near 5 mg/kg/day.

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

Investigators have reported good progress in determining how the disease works in the eye; however, a downside is the inflammation that seems to accompany treatment with increased dosing.

A poll for retina specialists regarding their attendance at the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois. The poll is now closed.

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois, from September 30 to October 3, featuring Subspecialty Days and a virtual component.

Automated quantitative fluid analyses are enabling personalised treatments, better patient outcomes

Oral APX3330 was found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 prior trials of APX3330.

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.

According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.

According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.

Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.

A synopsis of the findings presented at EURETINA 2022 for ophthalmologists and retina specialists.

According to data from Prevent Blindness, there were more than 26,000 sports-related eye injuries treated in the United States last year.

The white noise and classical music listened to by the preterm infants during ROP examinations showed positive effects on pain and heart rate and oxygen saturation values.

At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.

They advised that clinicians should be aware of this spectrum of retinal involvement after COVID-19 infections and emphasized the importance of a fundus evaluation.

The investigators explained that elevated angle-closure-related intraocular pressure may aggregate the visual impairment in patients with retinitis pigmentosa.

The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.